Loading...
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome
Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders characterized by low blood counts and a propensity to develop acute myeloid leukemia. The management of lowerrisk (LR) MDS with persistent cytopenias remains suboptimal. Eltrombopag, a thrombopoietin-receptor agonist, can improv...
Saved in:
| Published in: | Haematologica |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Fondazione Ferrata Storti
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7716353/ https://ncbi.nlm.nih.gov/pubmed/33256377 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2020.249995 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|